Patient-Reported and Neurocognitive Outcomes in Patients Treated with Axicabtagene Ciloleucel
Conclusions: This study is the first to our knowledge to report on both PROs and neurocognitive outcomes in patients treated with CAR T-cell therapy. Results indicate that moderate-to-severe patient-reported symptoms were transient following axi-cel, although a majority of patients reported ongoing, low-grade symptoms at 90 days post-treatment. Quality of life and neurocognition did not significantly change over time. These preliminary findings warrant larger future studies with longer follow-up to better understand changes in PROs and neurocognition in cancer survivors treated with CAR-T.DisclosuresJim: Janssen: Consultancy; RedHill Biopharma: Consultancy. Locke: Kite Pharma: Other: Scientific Advisor; Novartis Pharmaceuticals: Other: Scientific Advisor; Cellular BioMedicine Group Inc.: Consultancy.
Source: Blood - Category: Hematology Authors: Jim, H. S. L., Hoogland, A. I., Collier, A., Booth-Jones, M., Jain, M. D., Locke, F. L. Tags: 904. Outcomes Research-Malignant Conditions: Poster I Source Type: research
More News: Brain | Cancer | Cancer & Oncology | Chemotherapy | Clinical Trials | Constipation | Insomnia | Lymphoma | Men | Neurology | Neuroscience | Oral Cancer | Pain | Pharmaceuticals | Study | Toxicology